Valbiotis Company Description

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France.

The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis.

The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laboratory, LAPEC, MEDiS Unit, M2iSH, Clermont-Ferrand Clinical Investigation Center, ADECAL, and IFREMER.

Valbiotis SA was incorporated in 2014 and is based in Périgny, France.

Valbiotis SA

Country	France
Founded	2014
Industry	Biotechnology
Sector	Healthcare
Employees	44
CEO	Sebastien Peltier

Contact Details

Address: Rue Paul Vatine Périgny, 17180 France
Phone	33 5 46 28 62 58
Website	valbiotis.com

Stock Details

Ticker Symbol	ALVAL
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0013254851
SIC Code	2834

Key Executives

Name	Position
Sebastien Peltier HDR, Ph.D.	Co-Founder, Chairman of the Management Board and Chief Executive Officer
Stanislas Sordet	Chief Financial Officer and Member of Management Board
Sebastien Bessy	Chief Operating Officer and Member of the Management Board
Pascal Sirvent Ph.D.	CSO and Member of the Management Board
Murielle Cazaubiel	CMO and Member of the Management Board
Charlotte Jezequel	Director of Human Resources and Member of Management Board
Dr. Josep Infesta	Head of Global Business Development